Literature DB >> 22000198

Assessment of platelet transfusion for reversal of aspirin after traumatic brain injury.

Arshad M Bachelani1, Joshua T Bautz, Jason L Sperry, Alain Corcos, Mazen Zenati, Timothy R Billiar, Andrew B Peitzman, Gary T Marshall.   

Abstract

BACKGROUND: Platelet transfusion is utilized increasingly for traumatic brain injury (TBI) for the reversal of aspirin (ASA) therapy. Assessment of platelet inhibition and reversal by platelet transfusion after TBI has not been adequately characterized.
METHODS: A retrospective cohort analysis of TBI patients at a level I trauma center (January 2008-December 2009) was performed. The Aspirin Response Test (ART; VerifyNow) was used to assess platelet inhibition in TBI patients and guide platelet transfusion in patients with ASA-induced suppression. A follow-up ART was obtained after platelet administration. Primary endpoints were progression of intracranial hemorrhage on computed tomography, need for craniotomy, and mortality.
RESULTS: We analyzed 84 patients (median age, 78 [interquartile range, 64-86)]; 54% male). ASA use was documented in 36 (42%) patients. Initial ART indicated platelet dysfunction in 54 (64%) patients, including 42% of patients without a documented history of ASA use. Of the patients with a documented history of ASA, 2.4% had a normal ART. Of those with an initial ART of <550 ASA response units, 45 received platelets. Repeat ART demonstrated reversal of inhibition in 29 patients (64.4%). Initial responders to transfusion received a greater volume of platelets, suggesting a dose-response relationship. Logistic regression revealed a trend toward higher mortality in nonresponders to transfusion (P = .09). Receiver operating characteristic curve analysis revealed that ART results increased prediction of poor outcome compared with ASA history alone (area under the curve = 0.760 and 0.775, respectively).
CONCLUSION: The ART should be used to better target and guide platelet transfusions in TBI patients with known or suspected ASA use history. Patients with occult platelet dysfunction can be identified, unnecessary platelet transfusions avoided, and the adequate volume of platelets administered to correct drug-induced dysfunction. A dose-response relationship between quantity of platelets transfused and reversal of ASA inhibition was observed.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22000198     DOI: 10.1016/j.surg.2011.07.059

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  25 in total

1.  Relationship of Coagulopathy and Platelet Dysfunction to Transfusion Needs After Traumatic Brain Injury.

Authors:  Grace Martin; Dhavan Shah; Nora Elson; Ryan Boudreau; Dennis Hanseman; Timothy A Pritts; Amy T Makley; Brandon Foreman; Michael D Goodman
Journal:  Neurocrit Care       Date:  2018-06       Impact factor: 3.210

2.  Effects of Pre-Injury Anti-Platelet Agents on Short-Term Outcome of Patients with Mild Traumatic Brain Injury: A Cohort Study.

Authors:  Davood Farsi; Parviz Karimi; Mani Mofidi; Babak Mahshidfar; Mahdi Rezai; Peyman Hafezimoghadam; Saeed Abbasi
Journal:  Bull Emerg Trauma       Date:  2017-04

3.  Utility of the Aspirin and P2Y12 Response Assays to Determine the Effect of Antiplatelet Agents on Platelet Reactivity in Traumatic Brain Injury.

Authors:  Phillip V Parry; Phillip A Choi; Joshua S Bauer; David M Panczykowski; Ava M Puccio; David O Okonkwo
Journal:  Neurosurgery       Date:  2017-01-01       Impact factor: 4.654

4.  Use of Aspirin and P2Y12 Response Assays in Detecting Reversal of Platelet Inhibition With Platelet Transfusion in Patients With Traumatic Brain Injury on Antiplatelet Therapy.

Authors:  Phillip A Choi; Phillip V Parry; Joshua S Bauer; Benjamin E Zusman; David M Panczykowski; Ava M Puccio; David O Okonkwo
Journal:  Neurosurgery       Date:  2017-01-01       Impact factor: 4.654

5.  [Traumatic brain injury in anticoagulated patients : Hemostatic therapy for the treatment of intracranial hemorrhage].

Authors:  C Beynon; A W Unterberg
Journal:  Unfallchirurg       Date:  2017-03       Impact factor: 1.000

6.  The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Jacques Duranteau; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Marc Maegele; Giuseppe Nardi; Louis Riddez; Charles-Marc Samama; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2019-03-27       Impact factor: 9.097

Review 7.  Point of care and factor concentrate-based coagulation algorithms.

Authors:  Oliver M Theusinger; Philipp Stein; Jerrold H Levy
Journal:  Transfus Med Hemother       Date:  2015-03-20       Impact factor: 3.747

Review 8.  Management of bleeding and coagulopathy following major trauma: an updated European guideline.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2013-04-19       Impact factor: 9.097

9.  Post-TBI splenectomy may exacerbate coagulopathy and platelet activation in a murine model.

Authors:  Mackenzie C Morris; Devin John; Kathleen E Singer; Ryan Moran; Emily McGlone; Rosalie Veile; Holly S Goetzman; Amy T Makley; Charles C Caldwell; Michael D Goodman
Journal:  Thromb Res       Date:  2020-08-07       Impact factor: 3.944

10.  The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition.

Authors:  Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund A M Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Donat R Spahn
Journal:  Crit Care       Date:  2016-04-12       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.